PI3K isoforms in myeloid cells, both p110γ and p110δ, promote immune suppression and tumor neovascularization during antiangiogenic therapy, and inhibiting PI3K in these cells may improve the effectiveness of antiangiogenic therapy in PyMT mammary cancer models (Rivera et al., 2015). The gene discussed is PIK3CB; the disease is breast cancer.